Perkins Capital Management Inc Tyme Technologies, Inc. Transaction History

Perkins Capital Management Inc

$102 Million
Q2 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2020 Oct 28, 2020	SELL	$0.93 - $1.35 $113,692 - $165,037	-122,250 Closed	0 $0
Q1 2020 Apr 29, 2020	SELL	$0.9 - $1.95 $16,875 - $36,562	-18,750 Reduced 13.3%	122,250 $134,000
Q4 2019 Feb 03, 2020	SELL	$1.0 - $1.49 $1,500 - $2,235	-1,500 Reduced 1.05%	141,000 $197,000
Q3 2019 Oct 23, 2019	BUY	$0.97 - $1.77 $60,140 - $109,740	62,000 Added 77.02%	142,500 $170,000
Q2 2019 Aug 09, 2019	SELL	$0.96 - $1.89 $4,560 - $8,977	-4,750 Reduced 5.57%	80,500 $98,000
Q1 2019 Apr 22, 2019	SELL	$1.76 - $3.73 $23,144 - $49,049	-13,150 Reduced 13.36%	85,250 $150,000
Q4 2018 Feb 11, 2019	SELL	$2.01 - $4.21 $12,562 - $26,312	-6,250 Reduced 5.97%	98,400 $363,000
Q3 2018 Oct 22, 2018	BUY	$2.18 - $3.44 $7,848 - $12,384	3,600 Added 3.56%	104,650 $291,000
Q2 2018 Aug 02, 2018	BUY	$2.05 - $4.09 $158,977 - $317,179	77,550 Added 330.0%	101,050 $319,000
Q1 2018 Apr 23, 2018	BUY	$2.12 - $7.0 $49,820 - $164,500	23,500 New	23,500 $52,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Perkins Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Perkins Capital Management Inc with notifications on news.